Wednesday, June 18, 2014
Download Brochure

Application note : Parallel screening of 214 mutations with LungCartaTM Panel for clinical research

Agena Bioscience (formerly known as Sequenom) Massarray&trade system

LungCarta&trade Panel Introduction

List of genes & mutations included in the panel
  • Screen 214 mutations in 26 tumor suppressors and oncogenes in parallel.
  • Detect and quantify mutations with frequencies/abundance as low as 5%.
Compatible sample type
  • Fresh tumor samples
  • Frozen tumor samples
  • Formalin fixed, paraffin embedded tissues (FFPE)
  • Cell lines
Click to see Test performance data


Results Reporting
After spectra are obtained on the MassARRAY Analyzer 4 System, the Typer software creates a set of oncomutation reports including a:
  • Mutation List: List of mutations that are above the mutation frequency cutoff
  • Uncertain Confidence Mutations: Table of uncertain confidence mutations with failed assays or partially failed assays that do not provide enough information to determine whether there are mutations or not.
  • Call Details: Additional information for user to check assays in detail and perform additional analysis if necessary (one report for each chip).
Application note abstract:

Sequenom's MassARRAY® System* enables sensitive and rapid somatic mutation profiling in non-small cell lung carcinoma (NSCLC) samples. A new research use only LungCarta Panel offers highly valuable content with 214 mutations in 26 tumor suppressors and oncogenes.
We evaluated the LungCarta Panel against known standards, NCI-60 cell line DNA, and formalin-fixed paraffin embedded lung adenocarcinoma samples, and demonstrate that the panel provides a robust method for confirmation of known mutations.

Download the application note

For more information, please contact us or visit agenabioscience.com

Top of Page

Home | About Us | What's New | Product | Promotion | Contact Us | eBiotrade.com

Copyright © 1999-2017 Gene Company Limited. All Rights Reserved.